交易 Arcturus Therapeutics Holdings Inc - ARCT 差价合约
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) develops RNA-based medicines using its proprietary lipid nanoparticle and self-amplifying mRNA platforms. The company’s pipeline includes vaccines, liver-targeted therapies, and respiratory treatments with partnerships across major global health organizations. Arcturus’s shares move with clinical trial progress, regulatory milestones, and investor sentiment toward the mRNA therapeutics sector.最新股票文章

SpaceX上市首日收涨19%——IPO后如何交易SpaceX SPCX差价合约
SpaceX(SPCX)于2026年6月12日在纳斯达克首次上市,开盘报150美元,收盘报160.95美元,较135美元的IPO发行价上涨19.2%。
08:41, 16 六月 2026


